$SNY just made a big move in the vaccine game. They’re acquiring a promising hepatitis B vaccine from a biotech partner, basically stacking their pipeline in a space with real long-term demand. With global health needs only growing and hepatitis B still a major challenge worldwide, this isn’t just a random buy, it’s a strategic add that could pay off over time. Deals like this remind you that big pharmas still chase real science with real markets instead of just chasing headlines. Think this kind of acquisition actually moves the needle for $SNY’s growth story, or is it more of a “slow and steady” play?